Expression And Clinical Significance of Transcription Factor GRHL1 In Acute Myeloid Leukemia

Background: Acute myeloid leukemia (AML) ranks sixth in the incidence of malignant tumors. It is the most common acute leukemia in adults with clinical and molecular heterogeneity of the bone marrow and lymphatic system.Objective: In this study, we aimed to explore the expression and clinical significance of GRHL1 in acute myeloid leukemia.Methods: RNA-seq data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) were analyzed combined with the related clinical data of patients with AML. Kaplan–Meier plot was constructed to assess survival differences. Log-rank test and correlation analysis were performed to evaluate the prognostic value and clinical significance of GRHL1 in patients with AML. Results: In this study, we found that patients with AML showed significant differences in the GRHL1 gene expression compared to normal bone marrow controls. Kaplan-Meier survival analysis revealed that low expression of GRHL1 was significantly associated with worse prognosis in patients with AML. Multiple omics analysis and correlation analysis revealed that aberrant alterations of known factors were significantly associated with GRHL1 expression, which confirmed GRHL1 as a protective intervention factor in patients with AML.Discussion: GRHL1 presented great potential in evaluating predicting prognostic values and clinical significance in patients with AML. GRHL1 might act as an important role in inhibiting the progression of tumors and serve as a protective factor for potential therapeutic strategies of AML. GRHL1 might provide a novel biomarker for precision oncology and benefit clinical cancer management.